Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 5/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718434 | 0.98 | CYP11B2 (0.43) | NOS1NOS3NOS2TDO2PDK2 | |
| SCHEMBL28763152 | 0.96 | NOS3 (0.42) | NOS1NOS3NOS2TDO2PDK2 | |
| SCHEMBL934667 | 0.92 | PDK2 (0.46) | NOS1NOS3NOS2PDK2FEN1 | |
| SCHEMBL30469945 | 0.92 | PDK2 (0.46) | NOS1NOS3NOS2PDK2FEN1 | |
| Potassium SCHEMBL29930626 | 0.90 | PDK2 (0.45) | NOS1NOS3NOS2PDK2FEN1 | |
| SCHEMBL1693643 | 0.83 | PDE10A (0.42) | — | |
| SCHEMBL1429509 | 0.83 | HTR1A (0.55) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL624461 | 0.82 | DHFR (0.42) | NOS1NOS3NOS2PDK2HTR1A | |
| SCHEMBL29748769 | 0.81 | IKBKB (0.46) | — | |
| SCHEMBL17477141 | 0.80 | HTR1D (0.43) | NOS1NOS3NOS2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167252-A1 | Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections | GUDMUNDSSON KRISTJAN | 2006-07-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167252-A1 | Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections | IRF3, IFNAR1, IL2 | NOS1 1846/4885NOS3 2138/4885NOS2 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.